Sickle Cell Disease
Author / Curator:
(1) Be concise.
(2) Be evidence-based. (Everything should have a reputable citation and resource)(3) Be clinically relevant. (Avoid unnecessary discussion of pathophysiology and epidemiology if it does not help clinical decision-making).
Top Teaching Points
This portion should be a brief background. It may include recommended sub-headers:
- Physiology / Pathophysiology
- Progression and Complications of Disease (i.e. what we get worried about)
All diagnosis information should be evidence-based only. Recommended sub-headers:
- Signs and Symptoms
- Differential Diagnosis (i.e. what else to look for)
- Physical Exam Findings
- Recommended Work-up (Evidence-based Labs / Imaging / Diagnostics)
All treatment information should include citations and evidence-based links. Recommended sub-headers:
- Non-pharmalogical treatment
- Pharmacological treatments
- Things to Avoid (e.g. dietary, medication restrictions)
Other Teaching Pearls
These should be short one-liners (with citations) of unique or interesting "pearls" that can offer teaching points for more advanced practitioners. (e.g. Losartan is the only ARB hypertensive agent that is associated with a lower incidence of gout attacks )
These are brief one-line summaries of relevant trials and studies. One recommendation is to like to discussion pages like WikiJournalClub for further information.
Ongoing controversies / New updates
What's the latest scuttlebutt? This is a place to include new guidelines, controversies, or other recent updates on the topic.
Core review articles / Guidelines:
ReferencesSickle Cell Disease
- Choi et al.: Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012;344:d8190.